Data from the GEICAM/9906 trial, presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024, provides independent confirmation of the predictive value of the Endocrine Activity Index (EAITM).1 In addition, results from a 12-year outcomes analysis from the CALGB 9741 trial that established EAI as a predictor of benefit from dose-dense chemotherapy in […]
News_old
Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting
Abstracts highlighting the value of the Endocrine Activity Index were presented at ASCO 2024. The first abstract (538) highlighted the prognostic value for patients with Stage II-III breast cancer. The second abstract (565) highlighted the added prognostic value to the Recurrence Score. Houston, TX, August 5, 2024 – Delphi Diagnostics, Inc. announces two abstracts highlighting […]
Delphi Diagnostics® Inc. Announces a Strategic Partnership with Protean BioDiagostics to Offer the Endocrine Activity Index
Working collaboratively with Protean BioDiagnostics, Inc. to offer the Endocrine Activity IndexTM (EAITM) will allow Delphi Diagnostics to expand the ability to participate in additional clinical trials, as well as begin an Early Access Program in the first half of 2024. Houston, TX, April 2, 2024 – Delphi Diagnostics, Inc. announces a strategic partnership with […]
Delphi DiagnosticsTM Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX Breast Recurrence Score®) in Node-Positive Breast Cancer
Published in the Journal of Clinical Oncology, SET2,3, and Recurrence Score were independent of each other and provided additive prognostic information when combined in post-menopausal patients with node-positive breast cancer. Houston, TX, March 09, 2023 – Delphi Diagnostics, Inc announces the publication entitled, “Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence […]
Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy. Those patients whose […]
Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio. Houston, TX, September 22, 2022 – Delphi DiagnosticsTM Inc. today announced that the United States Patent and Trademark Office has issued US11,459,617 on […]
SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens. Houston, TX, June 13 2022 – Delphi Diagnostics Inc. announced today the inclusion of Delphi’s proprietary Sensitivity to Endocrine Therapy test, […]
SET2,3TM index adds independent, complementary information to personalize breast cancer treatment
December 14, 2021 Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX Recurrence Score in an analysis of data from postmenopausal patients with hormone receptor-positive breast […]